Biologicals
In this section you will find Therapeutics Line of Treatment Biologicals market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Analytical Tool - Peptides in Oncology
€3,100.00Published by BioSeeker Group on Feb 21st, 2012A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More -
Analytical Tool - Cancer Therapeutic Antibodies
€3,949.00Published by BioSeeker Group on Feb 21st, 2012A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More -
Peptides in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 214 companies plus partners who are today developing 196 peptide drugs in 427 developmental projects in cancer across 157 different targets. In addition, there are 5 suspended drugs and another 109 drugs where development has been ceased. Learn More -
Biologicals in Oncology Drug Pipeline Update 2012
€2,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 669 companies plus partners who are today developing 1071 biological drugs in 2294 developmental projects in cancer across 408 different targets. In addition, there are 17 suspended drugs and another 676 drugs where development has been ceased. Learn More -
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More -
Cellular Therapy in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 67 companies plus partners who are today developing 51 cellular therapy drugs in 100 developmental projects in cancer across 19 different targets. In addition, there are 3 suspended drugs and another 61 drugs where development has been ceased. Learn More -
Analytical Tool - Antibodies and Peptides in Oncology
€5,950.00Published by BioSeeker Group on Feb 21st, 2012A unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody and peptide cancer R&D and business development. Learn More -
Proteins in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 306 companies plus partners who are today developing 332 protein drugs in 570 developmental projects in cancer across 154 different targets. In addition, there are 2 suspended drugs and another 164 drugs where development has been ceased. Learn More -
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
€2,450.00Published by BioSeeker Group on Nov 14th, 2011This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Learn More -
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
€2,450.00Published by BioSeeker Group on Sep 27th, 2011This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More -
Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics
€2,692.00Published by Kalorama Information on Jul 1st, 2011The line between drug delivery and drug substance will continue to become more elusive in the near future as shown in the analysis, as researchers work to improve drug properties... Learn More -
Biomarkers: Technological and Commercial Outlook 2011-2021
€1,968.00Published by Visiongain on Jun 22nd, 2011Discover the pharma and diagnostics opportunities there What are the commercial prospects for biomarkers in pharma and diagnostics? Our new report shows you commercial opportunities for biomarkers, predicting future trends... Learn More -
Biosimilars and Follow-On Biologics: World Market 2011-2021
€1,968.00Published by Visiongain on Apr 11th, 2011you will see how the market can develop How will the biosimilars and follow-on biologics market develop this decade? Our new report shows you that emerging industry and market’s... Learn More -
RNAi for Therapeutic Applications: Market Prospects 2011-2021
€1,968.00Published by Visiongain on Mar 29th, 2011how you can discover the commercial opportunities in RNA interference How will the RNA interference (RNAi) therapies market develop this decade? Our new report shows you that emerging market’s revenue... Learn More -
Biomarkers in Alzheimer's Disease, 2011
Published by BioPharm Reports on Feb 23rd, 2011Regular Price: €1,842.00
Special Price: €1,659.00
This report brings together the latest advances in the identification of AD biomarkers and analyses the opportunities they offer in drug R&D and diagnostics. Learn More